Clinical Trial Update: Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) [Phase 2]

View source ↗

Summary

Phase 2 study of Fazirsiran (TAK-999, ARO-AAT) for Alpha-1 antitrypsin deficiency–associated liver disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Alpha-1 Antitrypsin Deficiency-associated Liver Disease

Drugs mentioned

• Fazirsiran (TAK-999, ARO-AAT) (Fazirsiran)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2025-04-20